Granted Patent B2

US 12,465,617 · App. 16/693,050 · Granted Nov 11, 2025

Inventors: Sarnath Chattaraj (Simi Valley, CA); Kiem H. Dang (Thousand Oaks, CA); Hsi Chung Fusselman (Simi Valley, CA); Poonam S. Gulati (La Canada, CA); Lance P. Hoffman (West Hollywood, CA); Guangping Zhang (Calabasas, CA)

Assignee: Medtronic MiniMed, Inc.

A61K31/727A61K38/28A61L29/08A61L29/16A61M5/14248A61M5/158A61L2300/236A61L2300/41A61L2300/42A61M2005/1586A61M5/16827A61M5/16836A61M2205/0205A61M2205/0238

Abstract

Claims (25)

1 . A system for delivering insulin to a diabetic patient at a single site of infusion over a period of time, the system comprising: a medication reservoir comprising an insulin solution; a cannula adapted for subcutaneous insertion into a tissue of a diabetic patient at the single site of infusion; a fluid conduit in operable contact with the medication reservoir and the cannula and adapted to deliver insulin from the medication reservoir to the single site of infusion; a site loss mitigating agent comprising rapamycin that inhibits inflammation at the single site of infusion; and wherein the system delivers an amount of rapamycin sufficient to inhibit inflammation at the single site of infusion for a period of time of at least 4 days.

2 . The system of claim 1 , wherein the site loss mitigating agent is:

(a) disposed within a depot and adapted to contact the insulin solution as the insulin solution flows from the medication reservoir to the single site of infusion; and/or

(b) pre- or in-situ mixed with insulin and/or

(c) which coats the cannula.

3 . The system of claim 2 , wherein the depot includes a membrane and/or a filter and/or a sponge and/or a polymeric material and/or a metal comprising rapamycin.

4 . The system of claim 1 , wherein the system further comprises dextran adapted to contact the insulin solution.

5 . The system of claim 4 , wherein the dextran is administered to the patient at a concentration between 0.0005 and 0.4 mg/kg/day.

6 . The system of claim 1 , wherein the period of time is at least 4, 5, 6, 7, 8 or 9 days.

7 . The system of claim 1 , wherein the site loss mitigating agent:

(a) coats the fluid path including cannula;

(b) coats a septum and/or the inner surface within the medication reservoir; or

(c) is disposed within a transdermal patch; and/or

(d) coats the cannula, internally or externally or both.

8 . A system for delivering insulin to a diabetic patient at a single site of infusion over a period of time, the system comprising:

a medication reservoir comprising an insulin solution;

a cannula adapted for subcutaneous insertion into a tissue of a diabetic patient at the single site of infusion;

a fluid conduit in operable contact with the medication reservoir and the cannula and adapted to deliver insulin from the medication reservoir to the single site of infusion; and

a rapamycin composition that inhibits inflammation at the single site of infusion; and

wherein the system delivers an amount of rapamycin sufficient to inhibit inflammation at the single site of infusion for a period of time of at least 4 days.

9 . The system of claim 8 , wherein the system further delivers rapamycin according to at least one delivery profile including:

(a) an immediate release profile wherein the rapamycin is administered to the patient from 0 to 6 hours following insertion of the cannula; and

(b) an extended release profile wherein the response-inhibiting agent is administered to the patient for at least 48 hours following insertion of the cannula.

10 . The system of claim 8 , wherein the system further comprises dextran adapted to contact the insulin solution.

11 . The system of claim 10 , wherein the dextran is administered to the patient at a concentration between 0.0005 and 0.4 mg/kg/day.

Assignments (2)

Continuity (5)

References Cited (189)